Trial Profile
A Study to Investigate the Cardiovascular Effects of Lasmiditan in Healthy Elderly Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Jan 2020
Price :
$35
*
At a glance
- Drugs Lasmiditan (Primary)
- Indications Migraine
- Focus Pharmacodynamics
- Sponsors Eli Lilly and Company
- 30 May 2018 Status changed from active, no longer recruiting to completed.
- 13 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 19 Mar 2018 Planned End Date changed from 1 Mar 2018 to 1 Apr 2018.